Lantern Pharma to Host Webinar on Open-Medicine AI Subsidiary

Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, has announced it will host a live webinar on September 23 at 12:30 p.m. Eastern to present the business model, development roadmap, and value proposition of Open-Medicine AI (“OMAI”), its wholly owned subsidiary. OMAI is developing a multi-agentic AI platform designed for end-to-end therapeutic development. The session will be led by Panna Sharma, founder and CEO of Open-Medicine AI, who will cover the OMAI platform architecture, expansion beyond rare cancers into additional disease categories and therapeutic modalities, and its planned subscription and enterprise licensing business model. This webinar offers stakeholders an opportunity to understand how OMAI aims to revolutionize therapeutic development through AI.

Lantern Pharma leverages its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR identifies patients most likely to benefit from Lantern’s therapies and guides biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its CNS-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For more details, visit the full press release at https://ibn.fm/U9lmN. Investors can stay updated on LTRN news through the company’s newsroom at https://ibn.fm/LTRN.

The announcement was distributed via BioMedWire (“BMW”), a specialized communications platform focused on the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BMW is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution to millions of followers, and tailored corporate communications solutions. This infrastructure ensures that news like Lantern Pharma’s webinar reaches a wide audience of investors, influencers, and journalists.